Exploring New Methods for Purifying Therapeutic Oligonucleotides
These molecules have garnered attention for their potential to target currently undruggable disease-associated targets.
In a recent study published in the Journal of Chromatography A, researchers have made strides in enhancing the purification of therapeutic oligonucleotides (1). These molecules, including antisense oligonucleotides (ASOs), small interfering ribonucleic acids (siRNAs), and conjugates, have garnered attention for their potential to target currently undruggable disease-associated targets. As the demand for oligonucleotide-based therapies grows, the need for efficient purification protocols and analytical methods becomes increasingly critical.
Oligonucleotide synthesis and storage have long posed a challenge due to the generation of numerous compound-related impurities. These impurities can impact the safety and efficacy of oligonucleotide-based therapies, making the development of effective purification methods paramount. Among the existing purification techniques, ion-pair chromatography stands out as the standard method for separating and analyzing therapeutic oligonucleotides.
However, optimizing ion-pair chromatography has not been without its challenges. Mathematical modeling has the potential to enhance the accuracy and efficiency of this purification process, but its application has proven to be complex. While simple models may fall short when dealing with advanced single molecules, complex models remain inefficient for the industrial-scale optimization of oligonucleotide purification.
The experimental system employed in the study involved a traditional C18 column using (dibutyl)amine as the ion-pair reagent and acetonitrile as an organic modifier. The models were constructed and tested using three crude 16-mer oligonucleotides, each with varying degrees of phosphorothioation, along with their respective n – 1 and (P = O)1 impurities.
Phosphorothioation can be relevant in the context of C18 chromatography columns as it allows for the attachment of thiol-modified DNA or RNA molecules to these columns, enabling selective separation and purification of nucleic acids based on their affinity for the C18 stationary phase, making it a useful technique for therapeutic oligonucleotides isolation in analytical and preparative chromatography.
The results of the study demonstrated the effectiveness of the proposed models in predicting overloaded concentration profiles for different gradients of the organic modifier and column load. This development marks a significant step forward in optimizing the purification of therapeutic oligonucleotides, a crucial step in their development as potential treatments for various diseases.
This article was written with the help of artificial intelligence and has been edited to ensure accuracy and clarity. You can read more about our policy for using AI here.
Reference
Leśko, M.; Kaczmarski, K.; Jora, M.; Stavenhagen, K.; Leek, T.; Czechtizky, W.; Fornstedt, T.; Samuelsson, J. Strategies for Predictive Modeling of Overloaded Oligonucleotide Elution Profiles in Ion-Pair Chromatography. Journal of Chromatography A 2023, 1711, 464446. DOI:10.1016/j.chroma.2023.464446.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
